CLINICAL EVIDENCE

From scientific discovery to human evidence.

Two published randomised, placebo-controlled clinical trials evaluated VMK223 at 500 mg/day over 12 weeks and reported significant findings in selected inflammatory biomarkers and instrumentally measured skin parameters. Other research has explored metabolic outcomes using a multi-ingredient formulation, while consumer evaluations describe experience with finished products.

Explore published research →

Researcher consulting with a woman about human research

PUBLISHED HUMAN RESEARCH

Published standalone VMK223 studies.

Evidence for B. breve BB091109 ingredients

Three peer-reviewed controlled trials and two real-world consumer studies (VMK223 alone or in combination)

STANDALONE VMK223

Skin appearance

Pipino et al., 2026

Dermatol Ther (Heidelb)

DESIGN: Randomised, double-blind, placebo-controlled
PARTICIPANTS: Women aged 40–55; 34 randomised, 29 completed
PRODUCT / DURATION: VMK223 500 mg/day; 12 weeks
OUTCOMES: Instrumental skin measures: hydration, elasticity, wrinkles, pores, acne and melanin

STANDALONE VMK223

Inflammatory biomarkers

Motei et al., 2023

Front Microbiol

DESIGN: Randomised, double-blind, placebo-controlled
PARTICIPANTS: Women aged 40–55; 40 randomised, 30 analysed
PRODUCT / DURATION: VMK223 500 mg/day; 12 weeks + 4-week follow-up
OUTCOMES: CRP, IL-6, TNF-α, IL-10 and salivary hormones

COMBINATION TRIAL

Metabolic health

Beteri et al., 2024

Nutrients

DESIGN: Randomised, double-blind, placebo-controlled
PARTICIPANTS: Adults with prediabetes; 53 randomised, 45 completed
PRODUCT / DURATION: GOS + konjac glucomannan + B. breve-derived material; 12 weeks
OUTCOMES: HbA1c, fasting glucose and gut microbiota

OPEN-LABEL CONSUMER

Consumer use: skin

Y SKIN study

veMico technical report

DESIGN: Open-label; no control group
PARTICIPANTS: Adults aged 39–65; 79 enrolled, 73 analysed
PRODUCT / DURATION: Y SKIN (VMK223 500 mg); 30 days
OUTCOMES: Self-reported skin appearance and satisfaction

OPEN-LABEL CONSUMER

Consumer use: gut

Y GUT sensitive study

veMico technical report

DESIGN: Open-label; no control group
PARTICIPANTS: Adults aged 18–65 with ≥3 gut symptoms; 80 enrolled, 62 completed
PRODUCT / DURATION: GOS 1.5 g + VMK223 200 mg; 30 days
OUTCOMES: Self-reported gut symptoms and satisfaction

The two standalone VMK223 trials are shown separately from the Beteri combination trial and uncontrolled Y SKIN/Y GUT evaluations. Trial summaries refer to the preparations and study designs identified. Published studies: University of Roehampton research funded by veMico Ltd; consumer studies: internal technical reports.

Percentage reduction in CRP and IL-6 from baseline in VMK223 and placebo groups at week 12 — Motei et al. — within-group changes calculated from published means; p-values refer to separate between-group comparisons.

Measured skin improvement outcomes from baseline in VMK223 and placebo groups at week 12 — Pipino et al. — instrumental outcomes measured at week 12; full results and methods in the original publication.

CONSUMER EXPERIENCE

Consumer experience with finished products.

The Y SKIN and Y GUT sensitive consumer evaluations explored self-reported experiences with finished products in open-label, uncontrolled studies.

Y SKIN

In a 30-day consumer evaluation, 84% of 73 respondents completing both surveys reported healthier, more radiant-looking skin.

Y GUT sensitive

In a 30-day consumer evaluation, 82% of 62 participants completing the study reported improved perceived gut function with a formulation combining VMK223 and GOS.

Explore Consumer Experience →